ARX788 is a novel ADC formed by the combination of the antitubulin molecule amberstatin 269 and an anti-HER2 mAb; this drug significantly inhibited the growth of tumor cells in a T-DM1-resistant HER2-positive GC model in a preclinical study and was superior to T-DM1 [78, 79]. Here, ERBB2 is linked to gastric cancer.